Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Operating Expenses (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Operating Expenses data on record, last reported at $17.1 million in Q4 2025.

  • For Q4 2025, Operating Expenses changed 0.4% year-over-year to $17.1 million; the TTM value through Dec 2025 reached $68.1 million, up 33.72%, while the annual FY2025 figure was $68.1 million, 33.73% up from the prior year.
  • Operating Expenses reached $17.1 million in Q4 2025 per CTNM's latest filing, up from $14.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $18.1 million in Q1 2025 and bottomed at $5.1 million in Q1 2023.
  • Average Operating Expenses over 3 years is $12.7 million, with a median of $12.0 million recorded in 2023.
  • The widest YoY moves for Operating Expenses: up 94.13% in 2024, down 1.08% in 2024.
  • A 3-year view of Operating Expenses shows it stood at $9.7 million in 2023, then skyrocketed by 76.18% to $17.0 million in 2024, then rose by 0.4% to $17.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $17.1 million in Q4 2025, $14.9 million in Q3 2025, and $17.9 million in Q2 2025.